-Cymene Complexes of Ruthenium(II) As Antitumor Agents

Overview

Journal Molecules

Publisher MDPI

Specialty Biology

Date 2020 Nov 4

PMID 33142775

Citations 8

Authors

Maria Angeles Pujante-Galian

Sergio A Perez

Mercedes G Montalban

Guzman Carissimi

Marta G Fuster

Gloria Villora

Gabriel Garcia

Affiliations

Soon will be listed here.

Abstract

In this work, the cytotoxic behavior of six ruthenium(II) complexes of stoichiometry [(η--cymene)RuClL] (I-VI), L = 4-cyanopyridine (I), 2-aminophenol (II), 4-aminophenol (III), pyridazine (IV), and [(--cymene)RuClL]PF; L = cyanopyridine (V), L = 2-aminophenol(VI) towards three cell lines was studied. Two of them, HeLa and MCF-7, are human carcinogenic cells from cervical carcinoma and human breast cancer, respectively. A comparison with healthy cells was carried out with BGM cells which are monkey epithelial cells of renal origin. The behavior of complex II exhibits selectivity towards healthy cells, which is a promising feature for use in cancer treatment since it might reduce the side effects of most current therapies.

Citing Articles

Ruthenium -Cymene Complexes Incorporating Substituted Pyridine-Quinoline-Based Ligands: Synthesis, Characterization, and Cytotoxic Properties.

Kokkosi A, Garofallidou E, Zacharopoulos N, Tsoureas N, Diamanti K, Thomaidis N Molecules. 2024; 29(13).

PMID: 38999167 PMC: 11243419. DOI: 10.3390/molecules29133215.

A Comparison between Bulgarian Essential Oil from Two Different Locations.

Lechkova B, Benbassat N, Karcheva-Bahchevanska D, Ivanov K, Peychev L, Peychev Z Molecules. 2024; 29(9).

PMID: 38731460 PMC: 11085318. DOI: 10.3390/molecules29091969.

First-Row Transition Metal Complexes Incorporating the 2-(2'-pyridyl)quinoxaline Ligand (pqx), as Potent Inflammatory Mediators: Cytotoxic Properties and Biological Activities against the Platelet-Activating Factor (PAF) and Thrombin.

Margariti A, Papakonstantinou V, Stamatakis G, Demopoulos C, Machalia C, Emmanouilidou E Molecules. 2023; 28(19).

PMID: 37836742 PMC: 10574351. DOI: 10.3390/molecules28196899.

Myrcene: A Natural Compound Showing Anticancer Activity in HeLa Cells.

Pincigher L, Valenti F, Bergamini C, Prata C, Fato R, Amorati R Molecules. 2023; 28(18).

PMID: 37764505 PMC: 10537210. DOI: 10.3390/molecules28186728.

Anti-Inflammatory and Antimicrobial Properties of Thyme Oil and Its Main Constituents.

Vassiliou E, Awoleye O, Davis A, Mishra S Int J Mol Sci. 2023; 24(8).

PMID: 37108100 PMC: 10138399. DOI: 10.3390/ijms24086936.

References

Jakupec M, Galanski M, Arion V, Hartinger C, Keppler B . Antitumour metal compounds: more than theme and variations. Dalton Trans. 2007; (2):183-94. DOI: 10.1039/b712656p. View

Levina A, Mitra A, Lay P . Recent developments in ruthenium anticancer drugs. Metallomics. 2011; 1(6):458-70. DOI: 10.1039/b904071d. View

Iida J, Bell-Loncella E, Purazo M, Lu Y, Dorchak J, Clancy R . Inhibition of cancer cell growth by ruthenium complexes. J Transl Med. 2016; 14:48. PMC: 4751662. DOI: 10.1186/s12967-016-0797-9. View

Abid M, Shamsi F, Azam A . Ruthenium Complexes: An Emerging Ground to the Development of Metallopharmaceuticals for Cancer Therapy. Mini Rev Med Chem. 2015; 16(10):772-86. DOI: 10.2174/1389557515666151001142012. View

Lenis-Rojas O, Robalo M, Tomaz A, Carvalho A, Fernandes A, Marques F . Ru( p-cymene) Compounds as Effective and Selective Anticancer Candidates with No Toxicity in Vivo. Inorg Chem. 2018; 57(21):13150-13166. DOI: 10.1021/acs.inorgchem.8b01270. View

Zeng L, Gupta P, Chen Y, Wang E, Ji L, Chao H . The development of anticancer ruthenium(ii) complexes: from single molecule compounds to nanomaterials. Chem Soc Rev. 2017; 46(19):5771-5804. PMC: 5624840. DOI: 10.1039/c7cs00195a. View

Singh S, Joshi S, Singh A, Saxena J, Pandey D . DNA binding and topoisomerase II inhibitory activity of water-soluble ruthenium(II) and rhodium(III) complexes. Inorg Chem. 2007; 46(25):10869-76. DOI: 10.1021/ic700885m. View

Morris R, Aird R, Murdoch P, Chen H, Cummings J, Hughes N . Inhibition of cancer cell growth by ruthenium(II) arene complexes. J Med Chem. 2001; 44(22):3616-21. DOI: 10.1021/jm010051m. View

Scolaro C, Chaplin A, Hartinger C, Bergamo A, Cocchietto M, Keppler B . Tuning the hydrophobicity of ruthenium(II)-arene (RAPTA) drugs to modify uptake, biomolecular interactions and efficacy. Dalton Trans. 2007; (43):5065-72. DOI: 10.1039/b705449a. View

10.

Kostova I . Ruthenium complexes as anticancer agents. Curr Med Chem. 2006; 13(9):1085-107. DOI: 10.2174/092986706776360941. View

11.

Zhao R, Hammitt R, Thummel R, Liu Y, Turro C, Snapka R . Nuclear targets of photodynamic tridentate ruthenium complexes. Dalton Trans. 2009; (48):10926-31. DOI: 10.1039/b913959a. View

12.

Zhang C, Lippard S . New metal complexes as potential therapeutics. Curr Opin Chem Biol. 2003; 7(4):481-9. DOI: 10.1016/s1367-5931(03)00081-4. View

13.

Ballester F, Ortega E, Porto V, Kostrhunova H, Davila-Ferreira N, Bautista D . New half-sandwich ruthenium(ii) complexes as proteosynthesis inhibitors in cancer cells. Chem Commun (Camb). 2019; 55(8):1140-1143. DOI: 10.1039/c8cc09211g. View

14.

Gill M, Thomas J . Ruthenium(II) polypyridyl complexes and DNA--from structural probes to cellular imaging and therapeutics. Chem Soc Rev. 2012; 41(8):3179-92. DOI: 10.1039/c2cs15299a. View

15.

Hartinger C, Jakupec M, Zorbas-Seifried S, Groessl M, Egger A, Berger W . KP1019, a new redox-active anticancer agent--preclinical development and results of a clinical phase I study in tumor patients. Chem Biodivers. 2008; 5(10):2140-2155. DOI: 10.1002/cbdv.200890195. View

16.

Liu P, Jia J, Zhao Y, Wang K . Recent Advances on Dark and Light-Activated Cytotoxity of Imidazole-Containing Ruthenium Complexes. Mini Rev Med Chem. 2015; 16(4):272-89. DOI: 10.2174/1389557516666151120120524. View

17.

Bugarcic T, Novakova O, Halamikova A, Zerzankova L, Vrana O, Kasparkova J . Cytotoxicity, cellular uptake, and DNA interactions of new monodentate ruthenium(II) complexes containing terphenyl arenes. J Med Chem. 2008; 51(17):5310-9. DOI: 10.1021/jm8003043. View

18.

Smith G, Therrien B . Targeted and multifunctional arene ruthenium chemotherapeutics. Dalton Trans. 2011; 40(41):10793-800. DOI: 10.1039/c1dt11007a. View

19.

Romero-Canelon I, Salassa L, Sadler P . The contrasting activity of iodido versus chlorido ruthenium and osmium arene azo- and imino-pyridine anticancer complexes: control of cell selectivity, cross-resistance, p53 dependence, and apoptosis pathway. J Med Chem. 2013; 56(3):1291-300. DOI: 10.1021/jm3017442. View

20.

Zaki M, Hairat S, Aazam E . Scope of organometallic compounds based on transition metal-arene systems as anticancer agents: starting from the classical paradigm to targeting multiple strategies. RSC Adv. 2022; 9(6):3239-3278. PMC: 9060267. DOI: 10.1039/c8ra07926a. View